ARID1A and neoplasm: Furthermore, in vitro experiments suggested that ARID1A knockdown (ARID1A-KD) activates the EGFR/PI3K/Akt/mTOR pathway and inhibits tumor cell autophagy, which attenuates inhibition of the Rig-I-like receptor pathway and production of type I interferon (IFN) in EGFR-mutant LUAD cells.